Cadrenal Therapeutics Inc (CVKD)

12:16 PM

Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks

12:16 PM

Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView

Mar 13, 2025

Mar 13, 2025

Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph

Mar 13, 2025

Mar 13, 2025

Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan

Mar 13, 2025

Mar 07, 2025

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree

Mar 07, 2025

Mar 05, 2025

(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 05, 2025

Mar 05, 2025

Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance

Mar 05, 2025

Mar 04, 2025

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks

Mar 04, 2025

Mar 04, 2025

Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance

Mar 04, 2025

Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace

Mar 04, 2025

Mar 04, 2025

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Can Cadrenal's Tecarfarin Revolutionize Treatment for HeartMate 3 LVAD Patients? - StockTitan

Mar 04, 2025

Mar 03, 2025

Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World

Mar 03, 2025

Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India

Feb 26, 2025

Feb 22, 2025

(CVKD) Trading Signals - Stock Traders Daily

Feb 22, 2025

Feb 12, 2025

(CVKD) Trading Advice - Stock Traders Daily

Feb 12, 2025

Feb 08, 2025

Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World

Feb 08, 2025

Feb 07, 2025

Biondi becomes managing partner at Flagship - BioCentury

Feb 07, 2025

Feb 07, 2025

Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks

Feb 07, 2025

Feb 07, 2025

Clinical Trials News Live Feed - StockTitan

Feb 07, 2025

Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer - MSN

Feb 06, 2025

Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK

Feb 06, 2025

Feb 06, 2025

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire

Feb 06, 2025

Feb 06, 2025

Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - StockTitan

Feb 06, 2025

Feb 05, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace

Feb 05, 2025

Feb 05, 2025

Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan

Feb 05, 2025

Jan 31, 2025

(CVKD) Investment Report - Stock Traders Daily

Jan 31, 2025

Jan 23, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World

Jan 23, 2025

Jan 21, 2025

Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals

Jan 21, 2025

Jan 21, 2025

Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily

Jan 21, 2025

Jan 13, 2025

Ponte Vedra biotech firm opens the Nasdaq - The Business Journals

Jan 13, 2025

Jan 10, 2025

(CVKD) Long Term Investment Analysis - Stock Traders Daily

Jan 10, 2025

Jan 09, 2025

Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan

Jan 09, 2025

Jan 09, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire

Jan 09, 2025

Jan 03, 2025

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World

Jan 03, 2025

Dec 31, 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire

Dec 31, 2024

Dec 22, 2024

AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World

Dec 22, 2024

Dec 21, 2024

Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World

Dec 21, 2024

Dec 20, 2024

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online

Dec 20, 2024

Dec 18, 2024

CVKDCadrenal Therape Latest Stock News & Market Updates - StockTitan

Dec 18, 2024

Dec 18, 2024

Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire

Dec 18, 2024

Dec 18, 2024

Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - StockTitan

Dec 18, 2024

Dec 09, 2024

(CVKD) Trading Report - Stock Traders Daily

Dec 09, 2024

Nov 23, 2024

What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World

Nov 23, 2024

Nov 20, 2024

CVKD: Recent Financings Raise $9.8 Million… - MSN

Nov 20, 2024

Nov 19, 2024

Kairos Pharma approved to dual list on Upstream - MSN

Nov 19, 2024

Nov 19, 2024

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan

Nov 19, 2024

Nov 18, 2024

(CVKD) Technical Data - Stock Traders Daily

Nov 18, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com

Nov 15, 2024